Skip to main content

Table 2 Association between PTGS2 genotypes and breast cancer risk in the Nurses' Health Study

From: A polymorphism in the 3' untranslated region of the gene encoding prostaglandin endoperoxide synthase 2 is not associated with an increase in breast cancer risk: a nested case-control study

SNP Genotype Cases (percentage) Controls (percentage) OR (95% CI)a
PTGS2_20417 G/G 865 (69.6) 1,185 (69.1) 1.00 (reference)
  G/C 336 (27.0) 485 (28.3) 0.93 (0.78–1.10)
  C/C 42 (3.4) 45 (2.6) 1.28 (0.82–2.02)
     p trend = 0.94
PTGS2_5277 G/G 875 (71.0) 1,217 (71.0) 1.00 (reference)
  G/C 322 (26.1) 464 (27.1) 1.00 (0.84–1.19)
  C/C 35 (2.8) 34 (2.0) 1.35 (0.81–2.26)
     p trend = 0.55
PTGS2_5209 T/T 834 (69.4) 1,171 (69.5) 1.00 (reference)
  T/G 330 (27.5) 472 (28.0) 0.97 (0.82–1.16)
  G/G 38 (3.2) 43 (2.6) 1.24 (0.77–2.00)
     p trend = 0.81
PTGS2_5275 T/T 541 (43.3) 699 (40.6) 1.00 (reference)
  T/C 567 (45.4) 808 (47.0) 0.88 (0.75–1.04)
  C/C 141 (11.3) 213 (12.4) 0.80 (0.62–1.03)
     p trend = 0.05
PTGS2_4648298 A/A 1,180 (95.4) 1,654 (96.3) 1.00 (reference)
  A/G + G/G 57 (4.6) 63 (3.7) 1.29 (0.88–1.88)
  1. aUnconditional logistic regression controlled for age, BMI at age 18 years, menopausal status at diagnosis, history of benign breast disease, and family history of breast cancer. CI, confidence interval; PTGS2, prostaglandin endoperoxide synthase 2; OR, odds ratio; SNP, single-nucleotide polymorphism.